OLEMA PHARMACEUTICALS

Olema Oncology to Present New Data Combining Palazestrant with Ribociclib at the San Antonio Breast Cancer Symposium

25 نوفمبر 2024 16:30:00 بحسب Nasdaq GlobeNewswire

Olema Oncology Reports Third Quarter 2024 Financial Results and Provides Corporate Update

12 نوفمبر 2024 15:01:00 بحسب Nasdaq GlobeNewswire

Olema Oncology to Participate in Upcoming Investor Conferences

06 نوفمبر 2024 06:01:11 بحسب Nasdaq GlobeNewswire

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

04 نوفمبر 2024 15:44:36 بحسب Nasdaq GlobeNewswire

Olema Oncology Presents Compelling New Preclinical Data Demonstrating Anti-Tumor Activity for OP-3136 with Enhanced Activity of Palazestrant Combinations at ENA 2024

23 أكتوبر 2024 06:00:00 بحسب Nasdaq GlobeNewswire

Olema Oncology Announces New Preclinical Combination Data to be Presented at the 2024 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

09 أكتوبر 2024 06:00:00 بحسب Nasdaq GlobeNewswire

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

02 أكتوبر 2024 15:30:00 بحسب Nasdaq GlobeNewswire

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

04 سبتمبر 2024 15:49:15 بحسب Nasdaq GlobeNewswire

Olema Oncology to Participate in Morgan Stanley 22nd Annual Global Healthcare Conference

21 أغسطس 2024 06:00:00 بحسب Nasdaq GlobeNewswire

Olema Oncology Reports Second Quarter 2024 Financial Results and Provides Corporate Update

06 أغسطس 2024 15:02:00 بحسب Nasdaq GlobeNewswire

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

02 أغسطس 2024 15:30:00 بحسب Nasdaq GlobeNewswire

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

02 يوليو 2024 15:29:00 بحسب Nasdaq GlobeNewswire

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

04 يونيو 2024 15:28:00 بحسب Nasdaq GlobeNewswire

Olema Oncology to Participate in Upcoming Investor Conferences in June

28 مايو 2024 06:03:00 بحسب Nasdaq GlobeNewswire

Olema Oncology Announces Promising New Data for Palazestrant in Combination with Ribociclib Presented at the 2024 ESMO Breast Cancer Congress

15 مايو 2024 06:01:00 بحسب Nasdaq GlobeNewswire

Olema Oncology Reports First Quarter 2024 Financial Results and Provides Corporate Update

08 مايو 2024 15:02:00 بحسب Nasdaq GlobeNewswire

Olema Oncology Announces New Clinical Data for Palazestrant in Combination with Ribociclib to be Presented at the 2024 ESMO Breast Cancer Annual Congress

08 مايو 2024 06:02:00 بحسب Nasdaq GlobeNewswire

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

02 مايو 2024 15:37:00 بحسب Nasdaq GlobeNewswire

Olema Oncology to Participate in Upcoming Investor Conferences in May

01 مايو 2024 06:02:00 بحسب Nasdaq GlobeNewswire

Olema Oncology to Participate in Canaccord Genuity 2024 Horizons in Oncology Virtual Conference

08 أبريل 2024 15:30:00 بحسب Nasdaq GlobeNewswire